← Karyopharm Therapeutics Inc.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash and Cash Equivalents, at Carrying Value | $49.7m | $69.0m | $118.0m | $128.9m | $85.9m | $190.5m | $135.2m | $52.2m | $62.5m | $60.5m | |
| Prepaid Expense and Other Assets, Current | $2.1m | $1.8m | $6.4m | $7.3m | $9.3m | $14.0m | $19.8m | $11.8m | $12.2m | $9.2m | |
| Cash, Cash Equivalents, and Short-term Investments | — | — | — | — | — | — | — | — | — | $63.7m | |
| Short-term Investments | $79.9m | $77.5m | — | — | — | — | — | — | — | — | |
| Inventory, Net | — | — | — | $346k | $2.6m | $4.1m | $4.2m | $3.0m | $4.7m | $4.0m | |
| Assets, Current | $131.6m | $148.4m | $334.6m | $278.6m | $276.5m | $275.6m | $350.2m | $233.9m | $156.5m | $103.1m | |
| Property, Plant and Equipment, Net | $2.8m | $2.2m | $3.9m | $3.0m | $2.2m | $1.6m | $1.1m | $606k | $400k | $104k | |
| Operating Lease, Right-of-Use Asset | — | — | — | $10.6m | $9.4m | $7.9m | $6.2m | $4.3m | $5.9m | $4.5m | |
| Additional Financial Items | |||||||||||
| Accrued Liabilities, Current | $11.4m | $21.4m | $32.5m | $40.9m | $52.9m | $69.1m | $58.4m | $61.4m | $60.7m | $64.5m | |
| Assets | $180.4m | $180.3m | $341.2m | $295.0m | $313.1m | $305.3m | $358.2m | $240.4m | $164.4m | $108.4m | |
| LIABILITIES AND EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Operating Lease, Liability, Current | — | — | — | $1.6m | $1.9m | $2.3m | $2.9m | $3.3m | $438k | $969k | |
| Accounts Payable, Current | $4.8m | $5.7m | $4.3m | $985k | $4.5m | $1.6m | $2.8m | $3.1m | $5.1m | $4.0m | |
| Operating Lease, Liability, Noncurrent | — | — | — | $13.2m | $11.3m | $9.0m | $6.1m | $2.8m | $6.7m | $5.7m | |
| Deferred Revenue, Current | — | $21.9m | $9.4m | $2.3m | $297k | — | — | — | — | — | |
| Deferred Revenue, Noncurrent | — | — | $4.5m | $2.2m | $0 | — | — | — | — | — | |
| Liabilities, Current | $16.5m | $49.5m | $46.9m | $46.4m | $60.2m | $73.7m | $65.9m | $69.5m | $92.3m | $92.1m | |
| Other Liabilities, Noncurrent | — | — | — | — | — | — | — | $978k | $2.4m | $11.1m | |
| Long-term Debt | — | — | — | — | — | $169.3m | — | — | — | — | |
| Liabilities | $18.1m | $50.8m | $158.0m | $245.2m | $262.5m | $385.0m | $374.8m | $376.6m | $350.4m | $401.3m | |
| Stockholders’ equity: | |||||||||||
| Preferred Stock, Value, Issued | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 | |
| Common Stock, Value, Issued | $4k | $5k | $6k | $7k | $7k | $8k | $12k | $12k | $13k | $14k | |
| Retained Earnings (Accumulated Deficit) | ($366.1m) | ($495.3m) | ($673.7m) | ($873.3m) | ($1.1b) | ($1.2b) | ($1.3b) | ($1.5b) | ($1.6b) | ($1.8b) | |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | ($274k) | ($217k) | ($244k) | ($37k) | $518k | $191k | ($638k) | ($161k) | ($356k) | $71k | |
| Additional Paid in Capital, Common Stock | $528.6m | $625.0m | $857.2m | $923.1m | $1.1b | $1.1b | $1.3b | $1.4b | $1.4b | $1.5b | |
| Stockholders' Equity Attributable to Parent | $162.2m | $129.5m | $183.2m | $49.8m | $50.5m | ($79.7m) | ($16.7m) | ($136.2m) | ($186.0m) | ($292.9m) | |
| Liabilities and Equity | $180.4m | $180.3m | $341.2m | $295.0m | $313.1m | $305.3m | $358.2m | $240.4m | $164.4m | $108.4m |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.